FDA staff objects, FDA approves anyway

Scientists at the FDA unanimously recommended rejecting the application of Cyberonics Inc. to sell its surgically implanted vagus nerve stimulator as a treatment for depression. The only clinical trial failed to show effectiveness. But Dr. Daniel G. Schultz, director of the FDA's Center for Devices and Radiological Health, decided to approve it anyway. Why, asks The New York Times?